The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

GPRC5D

19th Sep 2025

A plain language summary of the MonumenTAL-1 study: talquetamab for relapsed/ refractory multiple myeloma

This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. A phase 1 study is an early clinical trial where researchers evaluate how safe a medicine is at different doses in a small number of people. In the MonumenTAL-1 study, researchers looked at a new medicine under development called talquetamab, for people living with multiple myeloma (a type of blood cancer) who did not respond (refractory), stopped responding (relapsed) or who had difficulty dealing with their previous treatments.

9th Aug 2023

GPRC5D

A plain language summary of the MonumenTAL-1 study: talquetamab for relapsed/ refractory multiple myeloma

The MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma- a plain language summary